Perspective on a breast cancer genome sequencing study

Posted by  | Research

In today's lineup of stories covered by WNYC's radio program The Takeaway, Kimmel Cancer Center expert Josh Lauring, M.D., Ph.D., provides his perspective on a new study published yesterday in the journal Nature by the Wellcome Trust Sanger Institute. The study is an analysis of the genomic sequencing of 560 breast cancer patients. Listen to Lauring and radio host John(...)

One-third of patients with metastatic melanoma treated with immunotherapy drug nivolumab survive five years

Posted by  | Research

At the 2016 American Association for Cancer Research annual meeting today, scientists presented their results of a follow-up study tracking the survival of metastatic melanoma patients who were treated with the immunotherapy drug nivolumab. The drug is currently approved by the U.S. Food and Drug Administration for advanced lung and kidney cancers and advanced melanomas.(...)

Pay close attention to your overall health

Posted by  | Patient Stories

***Note: This is the final post of a four-part feature story, written by Elizabeth Huebeck. Read part one on Kristin's story, part two on cancer as a chronic disease and part three on Kristin's strategies for staying the course. Regardless of which treatment path cancer patients take, painful and uncomfortable side effects cannot be avoided. How(...)

Strategies for staying the course

Posted by  | Patient Stories

***Note: This is the third of a four-part feature story, written by Elizabeth Huebeck. Read part one on Kristin's story and part two on cancer as a chronic disease. Accepting primary control of your disease As a patient, Kristin Franceschi has learned that sometimes, after receiving the best standard practices of standard care, the cancer may return(...)

The model patient for cancer as chronic disease

Posted by  | Patient Stories

***Note: This is the second of a four-part feature story, written by Elizabeth Huebeck. Read part one on Kristin's story. Statistics show that the five-year survival rate for people diagnosed with Stage IV colon cancer is just 11 percent. Kristin Franceschi is beating the odds and now considers herself to be living with a chronic disease. As treatment modalities(...)

Kristin Franceschi hasn’t let Stage IV colon cancer slow her dance steps

Posted by  | Patient Stories

***This is the first of a four-part feature story, written by Elizabeth Huebeck. Read part two on cancer as a chronic disease, part three on Kristin's strategies for staying the course and part four on how Kristin monitors her health. About eight years ago, Kristin Franceschi—a tall, striking woman in her mid-fifties—began a new hobby that would(...)

Vice President Biden Speaks at Launch of Bloomberg~Kimmel Institute for Cancer Immunotherapy

Posted by  | Uncategorized

Vice President Joe Biden spoke to researchers, medical students, government leaders and others during the dedication of the new Bloomberg~Kimmel Institute for Cancer Immunotherapy. It was founded with gifts of $50 million each from Michael R. Bloomberg and Sidney Kimmel, and $25 million from more than a dozen additional supporters. Read the immunotherapy feature story(...)

Symposium Spotlight on Bladder Cancer

Symposium Spotlight on Bladder Cancer

Posted by  | Uncategorized

***This blog is the third in a three-part series on bladder cancer. Read parts one and two. The Johns Hopkins Greenberg Bladder Cancer Institute held its first public symposium with three leading bladder cancer experts providing novel new approaches to managing bladder cancer. “This institute, solely focused on bladder cancer, is the first one of(...)

Bivalacqua Directs Bladder Cancer Advocacy Network Meeting Panel

Posted by  | Uncategorized

***This blog is the second in a three-part series on bladder cancer. Read part one. Trinity Bivalacqua, M.D., Ph.D., director of urologic oncology in the James Buchanan Brady Urologic Institute and member of the Johns Hopkins Kimmel Cancer Center, co-chaired a panel discussion, “Data Sharing, Privacy Issues and Social Media,” at the Bladder Cancer Advocacy Network’s(...)